REMARKS

The restriction requirement has been maintained on the basis that classification of the various groups differs when the identity of "A" of formula I changes from a non-heterocycle to a heterocycle. However, since the claimed compounds contain a phenyl group and a urea group, searching of the heterocyclic classes should be redundant to the contents of the non-heterocyclic classes for the subject matter to be searched. Therefore, Applicants submit it should not be an undue burden to examine the full scope of the claims.

Information Disclosure Statement

Applicants will file a concise statement of relevance for the foreign language documents submitted with the Information Disclosure Statements as a separate submission. These will primarily be search reports in related applications. Applicants request that the English language documents identified in the IDS be considered now so as to expedite prosecution of this application.

Rejection Under 35 USC §103

Applicants submit that U.S. 6,143,764 is not prior art based on the priority claim to provisional application 60/122,064. The published PCT application has not been cited against the pending application and portions corresponding to U.S. 6,143,764 have not been identified. Therefore, this rejection should be withdrawn.

Based on the above remarks, Applicants respectfully request withdrawal of the restriction requirement, consideration of the English language references in the Information Disclosure Statements, and withdrawal of the rejection based on U.S. 6,143,764.

ļ

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

Richard J. Traverso (Reg. No. 30,595)

Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1, Suite 1400 2200 Clarendon Boulevard Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 6 P1

Date: September 17, 2002

RJT/lvb

K:\Bayer\6\p1\reply 9-17-02.dot